Skip to search formSkip to main contentSkip to account menu

velafermin

Known as: Recombinant FGF-20, Recombinant Human Fibroblast Growth Factor-20, rhFGF-20 
A recombinant human fibroblast growth factor-20 (rhFGF-20) protein with pro-proliferative activity. Velafermin stimulates DNA synthesis and cell… 
National Institutes of Health

Related topics

Related topics

3 relations
CG53135

Narrower (1)

CG53135-05

Broader (1)

FGF20 protein, human

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant
Goals of workThe objective of this study was to evaluate the safety and tolerability of velafermin in patients at risk of… 
2008
2008
Gateways to clinical trials. July-August 2008.
(-)-Epigallocatechin gallate, 501516, 89-12; Abatacept, Adalimumab, Adefovir dipivoxil, AG-701, Agatolimod sodium, Alefacept… 
2007
2007
Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats
Mucositis is a common, costly and unpleasant side effect of cancer chemotherapy and radiotherapy. Velafermin (FGF-20) has shown… 
Review
2007
Review
2007
A Randomized Placebo Controlled Phase II Trial of Prevention of Severe Oral Mucositis Using Single Dose Velafermin in Patients Receiving Myeloablative Therapy and Autologous Hematopoietic Stem Cell…
Oral mucositis (OM) is a commonly occurring side effect in patients (pts) undergoing AHSCT. Velafermin, recombinant human… 
2007
2007
Velafermin (rhFGF-20) reduces fractionated radiation- induced oral mucositis in hamsters
AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA 3758 Oral mucositis is a debilitating side effect of chemotherapy and… 
2006
2006
Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single dose velafermin (CG53135-05) for the prevention of oral mucositis.
6537 Background: Oral mucositis (OM) is a commonly occurring side effect of high-dose chemotherapy (HDCT) in patients (pts… 
2006
2006
Prokaryotic expression,purification and biological activity determination of recombinant human fibroblast growth factor-20 and preparation of its polyclonal antisera
Objective:To express and purify bioactive recombinant human fibroblast growth factor-20(rhFGF-20)protein and to prepare its… 
2006
2006
A phase II, multicenter, randomized, double-blind, placebo-controlled trial of the safety and efficacy of velafermin (CG53135-05) administered intravenously as a single dose for the prevention of…
2005
2005
Velafermin (CuraGen).
CuraGen is developing velafermin (CG-53135), human fibroblast growth factor-20 administered intravenously, for the potential… 
2005
2005
Single-Dose Prevention or Short-Term Treatment with Fibroblast Growth Factor-20 (CG53135-05)Reduces the Severity and Duration of Oral Mucositis.
Oral mucositis (OM) is a treatment-limiting condition associated with myelosupressive chemotherapy and radiation therapy. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)